Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caya Gel is a **non-hormonal, water-based contraceptive gel** intended for use with the Caya diaphragm and other barrier contraceptive methods to help prevent pregnancy. It is not a pharmaceutical spermicide and does **not** contain nonoxynol-9. Its contraceptive effect is described as a dual mechanism: the lactic-acid-containing formulation acidifies vaginal fluid to create a sperm-unfavorable environment, while the cellulose-based gel contributes a physical barrier in front of the cervix. The product is compatible with natural rubber latex and polyurethane condoms and has been described in Europe as a CE-marked Class IIa medical device rather than an FDA-approved drug in the United States. Based on the provided context, Caya Gel is best characterized as a contraceptive vaginal gel and medical device-associated product used as an adjunct to barrier contraception.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caya Gel.